EASY yields 0.37% · PFE yields 6.20%● Live data
📍 PFE pulled ahead of the other in Year 8
Combined, EASY + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EASY + PFE for your $10,000?
EASY invests in US large-cap companies with long records of paying and raising dividends, emphasizing businesses the Adviser defines as recession resistant. These are firms with steady demand for their products or services even during downturns, supported by low demand elasticity, recurring revenues, and high switching costs. They also typically show lower earnings volatility, more stable cash flows and less sensitivity to business cycles. EASYs approach combines top-down sector analysis with company-level screening to identify candidates with sustainable dividend policies and moderate to low revenue variability. The portfolio tends to tilt toward sectors such as consumer staples, utilities, pharmaceuticals, and technology but retains flexibility to adjust exposures as market conditions evolve. By focusing on companies with a demonstrated ability to maintain dividend growth through economic cycles, the fund seeks to balance capital appreciation with reliable income.
Full EASY Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.